MCID: CRV040
MIFTS: 50

Cervix Carcinoma

Categories: Cancer diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Cervix Carcinoma

MalaCards integrated aliases for Cervix Carcinoma:

Name: Cervix Carcinoma 11 14 71
Cancer of Cervix 11 28 5
Carcinoma of Cervix 11 28
Carcinoma of the Cervix Uteri 11
Carcinoma Cervix Uteri 11

Classifications:



External Ids:

Disease Ontology 11 DOID:2893
NCIt 49 C9039
SNOMED-CT 68 285432005
ICD10 31 C53 C53.9
UMLS 71 C0302592

Summaries for Cervix Carcinoma

Disease Ontology: 11 A cervical cancer that is located in the cervix uteri or located in the cervical area and that has material basis in abnormally proliferating cells derives from epithelial cells.

MalaCards based summary: Cervix Carcinoma, also known as cancer of cervix, is related to cervical cancer and cervical adenocarcinoma, and has symptoms including pelvic pain An important gene associated with Cervix Carcinoma is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Cell differentiation - expanded index and miRNAs involved in DNA damage response. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include cervix uteri, cervical area and cervix.

Related Diseases for Cervix Carcinoma

Diseases related to Cervix Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 420)
# Related Disease Score Top Affiliating Genes
1 cervical cancer 32.4 TP53 MIR27A MIR214 MIR21 MIR200A MIR15A
2 cervical adenocarcinoma 32.4 TP53 MIR9-1 MIR362 MAPK8IP1
3 endocervical carcinoma 32.3 TP53 MAPK8IP1 H2AC18
4 endometrial adenocarcinoma 31.4 TP53 MIR200A MIR199A1
5 serous cystadenocarcinoma 30.6 TP53 MIR21 MIR199A1 H2AC18
6 glioma 30.6 TP53 MIR21 MIR15A HOXA11-AS
7 endometriosis 30.5 TP53 MIR99A MIR200A MIR199A1 MIR141
8 brain glioma 30.5 TP53 MIR218-1 H2AC18
9 peripheral nervous system disease 30.4 TP53 MIR9-1 MIR362 MIR27A MIR24-1 MIR21
10 lymphoma, hodgkin, classic 30.4 TP53 MIR9-1 MIR21 MIR200A H2AC18
11 cervix small cell carcinoma 30.4 MIR199A1 MAPK8IP1
12 tongue squamous cell carcinoma 30.4 TP53 MIR99A MIR21 MIR199A1 MIR15A MIR149
13 oral squamous cell carcinoma 30.4 MIR99A MIR9-1 MIR27A MIR24-1 MIR214 MIR21
14 bone sarcoma 30.4 TP53 MIR9-1 MIR582 MIR27A MIR214 MIR199A1
15 endometrial cancer 30.3 TP53 MIR99A MIR21 MIR200A MIR199A1 MIR141
16 leukemia, acute myeloid 30.3 TP53 MIR9-1 MIR582 MIR362 MIR27A MIR21
17 lymphoma, non-hodgkin, familial 30.3 TP53 MIR9-1 MIR27A MIR214 MIR21 MIR200A
18 wilms tumor 1 30.3 TP53 MIR27A MIR199A1 H2AC18
19 lung cancer 30.1 TP53 MIR99A MIR9-1 MIR582 MIR362 MIR27A
20 anal squamous cell carcinoma 30.0 TP53 H2AC18
21 high-grade neuroendocrine carcinoma of the cervix uteri 11.7
22 glassy cell carcinoma of the cervix uteri 11.7
23 adenoid basal carcinoma of the cervix uteri 11.4
24 primitive neuroectodermal tumor of the cervix uteri 11.4
25 cervical clear cell adenocarcinoma 11.4
26 cervical endometrioid adenocarcinoma 11.4
27 papillary carcinoma of the cervix uteri 11.4
28 suppressor of tumorigenicity 3 11.2
29 cervical adenosquamous carcinoma 11.2
30 rare cancer of cervix uteri 11.2
31 malignant mixed epithelial and mesenchymal tumor of cervix uteri 11.2
32 cervical squamous cell carcinoma 11.1
33 exocervical carcinoma 11.0
34 cervical adenoid cystic carcinoma 11.0
35 cervical adenoid basal carcinoma 11.0
36 cervical large cell neuroendocrine carcinoma 11.0
37 cystadenocarcinoma 10.5 TP53 MIR21 MIR199A1
38 pulmonary blastoma 10.5 TP53 MIR9-1 MIR214
39 non-invasive bladder papillary urothelial neoplasm 10.5 TP53 MIR99A FGFR3
40 melanoma in congenital melanocytic nevus 10.5 TP53 MIR21 MIR199A1 H2AC18
41 ovarian clear cell carcinoma 10.5 TP53 MIR9-1 MIR21 MIR199A1 H2AC18
42 mature t-cell and nk-cell lymphoma 10.5 TP53 MIR21 MIR199A1 H2AC18
43 peripheral t-cell lymphoma 10.5 TP53 MIR21 MIR199A1 H2AC18 FGFR3
44 pleural disease 10.5 TP53 MIR21 MIR200A MIR199A1 H2AC18
45 low grade glioma 10.5 TP53 MIR9-1 MIR21 MIR199A1 H2AC18
46 central nervous system benign neoplasm 10.5 TP53 MIR9-1 MIR21 MIR199A1 H2AC18
47 human papillomavirus infectious disease 10.5 TP53 MIR21 MIR199A1 MIR149
48 oropharynx cancer 10.5 TP53 MIR99A MIR21 MIR199A1 H2AC18
49 skeletal muscle cancer 10.5 TP53 MIR9-1 MIR199A1 H2AC18
50 peripartum cardiomyopathy 10.5 MIR21 MIR199A1 MIR146A

Graphical network of the top 20 diseases related to Cervix Carcinoma:



Diseases related to Cervix Carcinoma

Symptoms & Phenotypes for Cervix Carcinoma

UMLS symptoms related to Cervix Carcinoma:


pelvic pain

Drugs & Therapeutics for Cervix Carcinoma

Drugs for Cervix Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
2
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
3
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
4
Metronidazole Approved Phase 2, Phase 3 443-48-1, 69198-10-3 4173
5
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
6 Albumin-Bound Paclitaxel Phase 3
7 Antimitotic Agents Phase 3
8 Tubulin Modulators Phase 3
9 Anti-Bacterial Agents Phase 2, Phase 3
10 Anti-Infective Agents Phase 2, Phase 3
11 Antiprotozoal Agents Phase 2, Phase 3
12 Antiparasitic Agents Phase 2, Phase 3
13 Antiviral Agents Phase 3
14 Antimetabolites Phase 3
15 Immunosuppressive Agents Phase 3
16
Mitomycin Approved Phase 2 50-07-7 5746
17
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4 254741536
18 Antiemetics Phase 2
19 Immunoglobulins Phase 1, Phase 2
20 Antibodies, Monoclonal Phase 1, Phase 2
21 Antibodies Phase 1, Phase 2
22 Antineoplastic Agents, Immunological Phase 1, Phase 2
23 Immunologic Factors Phase 1, Phase 2
24 Vaccines Phase 1, Phase 2
25
Pancrelipase Approved, Investigational 53608-75-6 8519
26
Proflavine Approved 92-62-6 7099
27 Liver Extracts
28 Pancreatin
29 Pharmaceutical Solutions
30 Anti-Infective Agents, Local
31 Fluorodeoxyglucose F18
32 Aluminum hydroxide, magnesium hydroxide, simethicone drug combination
33
TEMPO

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Assessment of the Impact of Preoperative Stress Reduction on Psychological, Physiological and Immunological Parameters in Women With Gynecological Malignancies - Prospective Randomized Controlled Trial Unknown status NCT00726635 Phase 3
2 A Prospective Randomized Trial of Neoadjuvant Chemotherapy and Surgery Versus Concurrent Chemoradiation Therapy in Patients With Stage IB2-IIB Squamous Carcinoma of the Uterine Cervix Unknown status NCT00193739 Phase 3 NACT;Inj.Cisplatin
3 A Randomized Clinical Trial of Radiotherapy and Metronidazole Versus Radiotherapy Alone in Anaemic Patients With Advanced Cervical Cancer In Mulago Completed NCT01937650 Phase 2, Phase 3 Radiotherapy plus metronidazole
4 Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study Completed NCT05149248 Phase 2, Phase 3
5 Phase 3 Randomized Comparison of Concurrent Gemcitabine, Cisplatin, and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Cancer of the Cervix Stages IIB to IVA Completed NCT00191100 Phase 3 Gemcitabine;Cisplatin
6 High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix Completed NCT00193830 Phase 3
7 Study of Two Fractions Versus Three Fractions High Dose Rate Brachytherapy in Locally Advanced Carcinoma of Uterine Cervix After Pelvic Concurrent Chemoradiotherapy - a Randomized Controlled Trial Completed NCT02765919 Phase 3
8 An Open Label Randomized Phase 2, Pilot Study to Investigate the Effectiveness of Palliative Chemotherapy in Stage IVB, Recurrent or Persistent Carcinoma Cervix Unknown status NCT02492503 Phase 1, Phase 2 Paclitaxel and carboplatin
9 Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer (SIDE, Advanced Squamous Cervical Cancer Trial) Unknown status NCT02879214 Phase 2
10 A Phase II Clinical Trial to Evaluate the Potential of Concomitant Chemoradiotherapy With Gemcitabine in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease Unknown status NCT03101995 Phase 2 Gemcitabine
11 Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression Completed NCT02309658 Phase 2 gemcitabine;cisplatin
12 A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy. Recruiting NCT04652076 Phase 1, Phase 2 NP137;Pembrolizumab;Paclitaxel;Carboplatin
13 A Safety Lead in Single Arm Phase II Study for Image Guided Ultrafractionated Radiation Therapy for Treatment of Metastatic Cervical Cancer Recruiting NCT05021237 Phase 2
14 A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients Active, not recruiting NCT02865135 Phase 1, Phase 2 DPX-E7 vaccine
15 A Randomized Phase II Trial of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Paclitaxel and Carboplatin in HIV-positive Women With Locally Advanced Cervical Cancer (LACC) Withdrawn NCT03834571 Phase 2 Carboplatin;Cisplatin;Paclitaxel
16 A Phase Ib Study Evaluating BGJ398 in Combination With Chemotherapeutic Regimen in Patients With Stage IV, Recurrent or Persistent Carcinoma of The Cervix and Other Solid Tumors Withdrawn NCT02312804 Phase 1 BGJ398;Carboplatin;Paclitaxel
17 Prospective, Randomised and Multi-centric Therapy Optimisation Study for Examining the Influence of Surgical Staging on the Oncological Results for Patients With Cervix Carcinoma of the FIGO Stages IIB-IV After Chemoradiation Unknown status NCT01049100
18 A Nonrandomized, Non-double Blinded Prospective Cohort Study to Evaluate the Preventive Efficacy of Quadrivalent HPV6/11/16/18 Vaccine for the Persistent Infection of HPV16 Genotype or HPV18 Genotype in Japanese Women Aged 27-45 Years. Unknown status NCT04022148
19 The Correlation Between the Haplotype of Human Leukocyte Antigen (HLA) and Human Papillomavirus Unknown status NCT00154479
20 Radiotherapy Assessments During Intervention ANd Treatment (RADIANT) Unknown status NCT03133286
21 Algorithm for Cervix Carcinoma Screening in the Czech Republic Using the Detection of HPV DNA With Selective HPV 16/18 Genotype and Special CINtec Plus Cytological Colouring Completed NCT05578833
22 Vaginal Length, Elasticity, Lubrication And Sexual Function In Women With Stage IB2 Cervix Carcinoma Completed NCT00053261
23 Predicting Outcome in Cervix Carcinoma: a Prospective Study Completed NCT01825005
24 A Pilot Study to Assess the Suitability of DCE-MRI for Detection of Vascular Changes After Vaginal Brachytherapy Completed NCT01991808
25 Hybrid PET/MR in the Therapy of Cervical Cancer: A Pilot Study Completed NCT01759355
26 Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix Completed NCT02206048 Proflavine
27 A Phase II Randomized Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix Completed NCT00193804
28 Concomitant Chemo-radiation in Advanced Stage Carcinoma Cervix: A Phase III Randomized Trial Completed NCT00193791
29 Para-Aortic Lymph Nodal Staging and Evaluation of Treatment Outcome by 18F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Advanced Cervical Cancer Completed NCT00193752
30 Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy Completed NCT04809727
31 High Intensity Interval Training (HIIT) on Stationary Bike With and Without Compression Stockings for Patients With Cancer-related Lymphedema in the Lower Limbs - a Feasibility Study Completed NCT03653819
32 Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic Irradiation Recruiting NCT04626466
33 The PIONEER Initiative: Precision Insights On N-of-1 Effectiveness Research. Tissue Ownership by the Individual With the Return of Actionable Information to the Individual Patient and Physician (Precision Oncology) Recruiting NCT03896958
34 Tempus Priority Study: An Observational Study of Patients Who Have Received Comprehensive Genomic Profiling Recruiting NCT05179824
35 SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry Recruiting NCT03452774
36 Minimally Invasive Therapy Versus Open Radical Hysterectomy (MITOR) for Management of Early Stage Cervical Cancer Not yet recruiting NCT04999696
37 Study Evaluating Predictive Value of Local Control at 19.8 (MRI and TEP Scan) for Patient With Stade I to IIIB Cervix Carcinoma Treated by Radiotherapy Terminated NCT01641484

Search NIH Clinical Center for Cervix Carcinoma

Genetic Tests for Cervix Carcinoma

Genetic tests related to Cervix Carcinoma:

# Genetic test Affiliating Genes
1 Cancer of Cervix 28 FGFR3
2 Carcinoma of Cervix 28

Anatomical Context for Cervix Carcinoma

Organs/tissues related to Cervix Carcinoma:

FMA: Cervix Uteri, Cervical Area
MalaCards : Cervix, Lymph Node, Bone, Liver, Uterus, Breast, Bone Marrow

Publications for Cervix Carcinoma

Articles related to Cervix Carcinoma:

(show top 50) (show all 2555)
# Title Authors PMID Year
1
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. 5
15772091 2005
2
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. 5
10471491 1999
3
Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. 5
8589699 1995
4
Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. 5
1349102 1992
5
Mutational hotspot in the p53 gene in human hepatocellular carcinomas. 5
1849234 1991
6
Biomarker Expression Profiling in Cervix Carcinoma Biopsies Unravels WT1 as a Target of Artesunate. 62
36316038 2022
7
Microbes in gynecologic cancers: Causes or consequences and therapeutic potential. 62
34302959 2022
8
A study for evaluating clinical relevance of circulating cell-free DNA in cervical cancer. 62
36412409 2022
9
Synthesis and preliminary evaluations of [18F]fluorinated pyridine-2-carboxamide derivatives for targeting PD-L1 in cancer. 62
36281866 2022
10
Determination and evaluation of HR-HPV genotype in different communities of Bihar, India. 62
36101850 2022
11
Antioxidant and cytotoxicity activities of δ-tocotrienol from the seeds of Allophylus africanus. 62
34852702 2022
12
Added-Value of Diffusion-Weighted Imaging (DWI) and Dynamic Contrast-Enhanced (DCE-MRI) Magnetic Resonance Imaging in the Preoperative Assessment of Cervical Cancer. 62
35923516 2022
13
Does diffusion weighted imaging have a prognostic value in differentiating gynecological diseases? 62
35490049 2022
14
Increased expression of squamous cell carcinoma antigen 1 and 2 in mycosis fungoides and Sézary syndrome 62
36301759 2022
15
[Clinicopathological features of mixed cervical carcinoma with adenoid cystic pattern]. 62
35785831 2022
16
Invasive stratified mucin-producing carcinoma of cervix: A case report. 62
35843813 2022
17
Antitumor Activity of Tubulin-Binding Agent MPC-6827 on Different Types of Cancer Cell Lines. 62
35988274 2022
18
Concurrent chemoradiation and brachytherapy alone or in combination with nelfinavir in locally advanced cervical cancer (NELCER): study protocol for a phase III trial. 62
35387819 2022
19
Two new triterpenoid fatty acid esters from Schefflera barteri Harms (Araliaceae)§. 62
33203260 2022
20
New cell cycle checkpoint pathways regulators with 2-Oxo-indoline scaffold as potential anticancer agents: Design, synthesis, biological activities and in silico studies. 62
35091290 2022
21
Soyauxinine, a New Indolopyridoquinazoline Alkaloid from the Stem Bark of Araliopsis soyauxii Engl. (Rutaceae). 62
35164367 2022
22
Influence of ligand lipophilicity in Pt(II) complexes on their antiproliferative and apoptotic activities in tumour cell lines. 62
34922157 2022
23
Three new iridoids from the aerial parts of Nepeta teucriifolia Willd. and antiproliferative activities of extracts. 62
35129012 2022
24
A Prospective Investigation of Tumor Hypoxia Imaging with 68Ga-Nitroimidazole PET/CT in Patients with Carcinoma of the Cervix Uteri and Comparison with 18F-FDG PET/CT: Correlation with Immunohistochemistry. 62
35207237 2022
25
Phototheranostics of Cervical Neoplasms with Chlorin e6 Photosensitizer. 62
35008375 2022
26
First report of compounds from an Ancistrocarpus species: Triterpenoids from A. densispinosus Oliv. (Malvaceae). 62
32598239 2022
27
Prognostic Analysis and Comparison of the 2014 and 2018 International Federation of Gynecology and Obstetrics Staging System on Overall Survival in Patients with Stage IIB-IVA Cervix Carcinoma. 62
35283649 2022
28
A novel cervix carcinoma biomarker: Pathological-epigenomics, integrated analysis of MethylMix algorithm and pathology for predicting response to cancer immunotherapy. 62
36408176 2022
29
Dosimetric Influence of Acuros XB Dose-to-Medium and Dose-to-Water Reporting Modes on Carcinoma Cervix Using Intensity-Modulated Radiation Therapy and Volumetric RapidArc Technique. 62
35548039 2022
30
Cervical Cancers: Varieties and the Lower Anogenital Squamous Terminology. 62
35928526 2022
31
Design, Synthesis, Spectroscopic Characterisation and In Vitro Cytostatic Evaluation of Novel Bis(coumarin-1,2,3-triazolyl)benzenes and Hybrid Coumarin-1,2,3-triazolyl-aryl Derivatives. 62
35163905 2022
32
Evolution in endoscopic endonasal approach for the management of hypothalamic-pituitary region metastasis: A single-institution experience. 62
35965539 2022
33
Imaging of Tumor Hypoxia With 18F-EF5 PET/MRI in Cervical Cancer. 62
34619699 2021
34
How to predict para-aortic node involvement in advanced cervical cancer? Development of a predictive score. A FRANCOGYN study. 62
34274203 2021
35
Morbidity following image-guided brachytherapy for cervical cancer: Patient and treatment related factors. 62
34380591 2021
36
Meleagrin from marine fungus Emericella dentata Nq45: crystal structure and diverse biological activity studies. 62
32189530 2021
37
New cyclopeptide alkaloids from the whole plant of Justicia procumbens L. 62
32347116 2021
38
Onosma mutabilis: Phytochemical composition, antioxidant, cytotoxicity, and acute oral toxicity. 62
34646543 2021
39
Cytotoxic Effect In Vitro of Acalypha monostachya Extracts over Human Tumor Cell Lines. 62
34834687 2021
40
Self-Assembly and Multifaceted Bioactivity of a Silver(I) Quinolinate Coordination Polymer. 62
34546735 2021
41
Isolated cystic liver metastasis in a case of squamous cell carcinoma of cervix. 62
33624562 2021
42
MRI accuracy and interobserver agreement in locally advanced cervix carcinoma. 62
34233471 2021
43
Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria. 62
34253389 2021
44
A Multicomponent Protocol for the Synthesis of Highly Functionalized γ-Lactam Derivatives and Their Applications as Antiproliferative Agents. 62
34451879 2021
45
Risk for second bladder and rectal malignancies from cervical cancer irradiation. 62
34021692 2021
46
Distribution of High-risk Human Papillomavirus Genotypes in Cervical Secretions in Punjab. 62
34271777 2021
47
Lifetime radiation-induced sarcoma risk in patients subjected to IMRT or VMAT for uterine cervix carcinoma. 62
33909230 2021
48
Survival in Cervical Cancer and Its Predictors at Ocean Road Cancer Institute From January to December 2012. 62
34010012 2021
49
Effects of Colchicum baytopiorum leaf extract on cytotoxicity and cell death pathways in C-4 I and Vero cell lines. 62
34268982 2021
50
[Clear Cell Carcinoma of Cervix in a 12-Year-Old Girl: A Case Report]. 62
34018378 2021

Variations for Cervix Carcinoma

ClinVar genetic disease variations for Cervix Carcinoma:

5 (show all 12)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TP53 NM_000546.6(TP53):c.747G>T (p.Arg249Ser) SNV Pathogenic
12352 rs28934571 GRCh37: 17:7577534-7577534
GRCh38: 17:7674216-7674216
2 FGFR3 NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) SNV Pathogenic
Pathogenic
16339 rs121913483 GRCh37: 4:1803568-1803568
GRCh38: 4:1801841-1801841
3 FGFR3 NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys) SNV Pathogenic
Pathogenic
16332 rs121913482 GRCh37: 4:1803564-1803564
GRCh38: 4:1801837-1801837
4 FGFR3 NM_000142.5(FGFR3):c.1138G>A (p.Gly380Arg) SNV Pathogenic
16327 rs28931614 GRCh37: 4:1806119-1806119
GRCh38: 4:1804392-1804392
5 FGFR3 NM_000142.5(FGFR3):c.1620C>G (p.Asn540Lys) SNV Pathogenic
16338 rs28933068 GRCh37: 4:1807371-1807371
GRCh38: 4:1805644-1805644
6 FGFR3 NM_000142.5(FGFR3):c.1949A>C (p.Lys650Thr) SNV Pathogenic
65855 rs121913105 GRCh37: 4:1807890-1807890
GRCh38: 4:1806163-1806163
7 FGFR3 NM_000142.5(FGFR3):c.749C>G (p.Pro250Arg) SNV Pathogenic
16340 rs4647924 GRCh37: 4:1803571-1803571
GRCh38: 4:1801844-1801844
8 FGFR3 NM_000142.5(FGFR3):c.1960-16T>C SNV Uncertain Significance
931624 rs1721900734 GRCh37: 4:1807968-1807968
GRCh38: 4:1806241-1806241
9 FGFR3 NM_000142.5(FGFR3):c.1993G>T (p.Ala665Ser) SNV Uncertain Significance
465350 rs764892330 GRCh37: 4:1808017-1808017
GRCh38: 4:1806290-1806290
10 FGFR3 NM_000142.5(FGFR3):c.2153A>G (p.Asn718Ser) SNV Uncertain Significance
521225 rs139773438 GRCh37: 4:1808395-1808395
GRCh38: 4:1806668-1806668
11 FGFR3 NM_000142.5(FGFR3):c.200G>A (p.Gly67Asp) SNV Uncertain Significance
546226 rs369232922 GRCh37: 4:1801071-1801071
GRCh38: 4:1799344-1799344
12 BRIP1 NM_032043.3(BRIP1):c.587A>G (p.Asn196Ser) SNV Likely Benign
128194 rs550707862 GRCh37: 17:59924502-59924502
GRCh38: 17:61847141-61847141

Expression for Cervix Carcinoma

Search GEO for disease gene expression data for Cervix Carcinoma.

Pathways for Cervix Carcinoma

GO Terms for Cervix Carcinoma

Cellular components related to Cervix Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.8 MIR99A MIR9-1 MIR582 MIR362 MIR27A MIR24-1
2 extracellular vesicle GO:1903561 9.43 MIR99A MIR27A MIR24-1 MIR214 MIR21 MIR15A

Biological processes related to Cervix Carcinoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell population proliferation GO:0008285 10.11 TP53 MIR9-1 MIR24-1 MIR218-1 MIR214 MIR21
2 positive regulation of apoptotic process GO:0043065 10.09 TP53 MIR27A MIR21 MIR15A MIR146A
3 negative regulation of gene expression GO:0010629 9.91 TP53 MIR9-1 MIR27A MIR214 MIR21 MIR199A1
4 negative regulation of inflammatory response GO:0050728 9.89 MIR199A1 MIR15A MIR149 MIR146A MIR141
5 negative regulation of angiogenesis GO:0016525 9.85 MIR24-1 MIR214 MIR21 MIR15A MIR146A
6 negative regulation of cell migration GO:0030336 9.85 MIR9-1 MIR24-1 MIR218-1 MIR214 MIR21 MIR149
7 negative regulation of glial cell proliferation GO:0060253 9.8 TP53 MIR146A
8 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.78 MIR27A MIR214 MIR21 MIR146A
9 miRNA-mediated gene silencing GO:0035195 9.77 MIR99A MIR9-1 MIR582 MIR362 MIR27A MIR24-1
10 negative regulation of vascular associated smooth muscle cell proliferation GO:1904706 9.76 MIR362 MIR214 MIR15A
11 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.73 MIR24-1 MIR21 MIR199A1
12 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.73 MIR146A MIR149 MIR21 MIR9-1
13 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.72 MIR149 MIR15A MIR24-1
14 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.71 MIR27A MIR21 MIR146A
15 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.71 MIR199A1 MIR15A MIR149 MIR146A
16 negative regulation of vascular endothelial growth factor production GO:1904046 9.7 MIR199A1 MIR15A MIR146A
17 cell growth involved in cardiac muscle cell development GO:0061049 9.63 MIR24-1 MIR199A1
18 positive regulation of connective tissue replacement GO:1905205 9.62 MIR214 MIR199A1
19 miRNA-mediated gene silencing by mRNA destabilization GO:0035279 9.62 MIR9-1 MIR27A MIR214 MIR146A
20 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.61 MIR27A MIR21
21 negative regulation of receptor signaling pathway via STAT GO:1904893 9.6 MIR99A MIR149
22 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.59 MIR214 MIR199A1
23 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.58 MIR146A MIR141
24 negative regulation of matrix metallopeptidase secretion GO:1904465 9.57 MIR199A1 MIR146A
25 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.55 MIR362 MIR218-1 MIR214 MIR21 MIR15A
26 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.5 MIR146A MIR15A MIR21 MIR218-1 MIR24-1 MIR27A

Molecular functions related to Cervix Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.7 TP53 MIR9-1 MIR27A MIR24-1 MIR214 MIR21
2 mRNA base-pairing translational repressor activity GO:1903231 9.5 MIR99A MIR9-1 MIR582 MIR362 MIR27A MIR24-1

Sources for Cervix Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....